Standardizing Organ-on-a-Chip in U.S. Drug R&D

The U.S. organ-on-a-chip market for drug development is projected to grow substantially by 2033, driven by regulatory advancements such as FDA guidance allowing use of non-animal testing methods. However, widespread adoption requires meeting strict operational and regulatory validation criteria for reproducibility, cost, and data compatibility in pharmaceutical workflows.

This Wire brief sits within Fusion42's coverage of Drug Discovery.